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OBJECTIVES: To examine the frequency and nature of
FDA regulatory actions against pharmaceutical compa-
nies for unsubstantiated or misleading economic and
quality-of-life (QOL) claims. 
METHODS: Review of publicly-available FDA warning
letters and notices of violation (n = 566) sent to pharma-
ceutical companies between January 1997 and November
2001 for inappropriate promotional claims. A standard
data collection form was developed to capture the 
frequency and type of violation and the medium in which
violations were found. We classiﬁed economic violations
into several categories (e.g., “unsupported comparative
claim of effectiveness, safety or interchangeability,”
“claims of cost-savings when there are obvious additional
costs that may affect cost savings,” “implied claims of
cost-savings to a broader audience than applicable”).
QOL violations for false or misleading claims using the
words improved ‘quality of life’ or ‘patient well-being’
were classiﬁed into the following categories: “lack of 
substantial evidence for QOL claims,” “promoting 
QOL claims in investigational or unapproved drug,” and
“selective presentation of QOL information”.
RESULTS: 28 (4.9%) letters cited false and/or mislead-
ing economic claims. The most common economic viola-
tion was an economic claim containing an “unsupported
comparative claim of effectiveness, safety or interchange-
ability” (n = 14). 28 (4.9%) letters cited QOL violations
(4 letters contained both economic and QOL violations).
The most common QOL violation was “lack of substan-
tial evidence for QOL claims” (n = 15). Violations were
found most frequently in brochures and on websites.
CONCLUSIONS: A body of evidence is emerging that
illustrates how the FDA is regulating promotional mate-
rial containing misleading or unsubstantiated economic
and QOL claims. Knowing what constitutes an economic
or QOL violation remains unclear, because there are no
formal guidelines about what constitutes a violation, nor
what level of substantiating evidence is required. More
guidance may be needed to ensure appropriate use in drug
promotions.
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RELATIONSHIP BETWEEN DIFFERENT
MEASURES OF ASTHMA SEVERITY: PATIENT-
PERCEIVED, SYMPTOM DERIVED,AND FEV1
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OBJECTIVE: In health services research, obtaining 
objective measures of pulmonary function to classify
asthma severity is often not possible. Researchers must
rely on methods such as frequency of self-reported symp-
toms and patient perceived severity. This study examined
the relationship between FEV1 determined severity and
severity determined by patient-reported information. 
METHODS: Data from adult patients with asthma were
obtained from a pulmonary clinic via chart review and
patient self-report during a scheduled physician visit.
Patients in acute exacerbation were excluded. Patient-
Perceived Severity (PPS) was determined by asking 
“How severe do you think your asthma is?” with a 
ﬁve-point Likert scale from Very Mild to Very Severe.
Overall Symptom-derived Severity (OSS) and Nocturnal
Symptom-derived Severity (NSS) were determined from
two separate questions regarding symptom frequency
during the preceding four weeks. Responses were based
on the NHLBI 1997 Asthma Guidelines. Pulmonary func-
tion tests were obtained the same day as part of standard
care. FEV1-Determined Severity (FEV1-DS) was derived
by comparing the FEV1 with the Guideline classiﬁcation
of severity based on spirometry. Three severity categories
were derived for each severity method. Percent agreement
between FEV1-DS and each patient-reported severity 
was determined by constructing 3 ¥ 3 tables. Correlations
(Spearman’s rho) were conducted between FEV1-DS and
the patient-reported severity measures.
RESULTS: 57 patients with a mean FEV1 percent 
predicted of 80.2% (27.5) were studied. The percent
agreement between FEV1-DS and PPS was 59.7%
(33.3% over-estimate, 7.0% under-estimate); 56.4%
between FEV1-DS and OSS (14.5% over-estimate, 
29.1% under-estimate); and 40.7% between FEV1-DS
and NSS (25.9% over-estimate, 33.3% under-estimate).
The correlations between FEV1-DS and PPS were 0.58 (p
< 0.01); 0.53 with OSS (p < 0.01); and 0.13 with NSS (p
= 0.13).
CONCLUSIONS: PPS and OSS demonstrated reasonable
agreement and correlation to FEV1-DS, albeit opposite
trends in over- and under-estimates. These two measures
of asthma severity appear useful for population based
studies when FEV1 is unavailable.
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OBJECTIVES: Several empiric algorithms have been
developed to derive preference estimates from the SF-36.
The objective of this study was to compare the validity
and responsiveness of SF-36 derived preference estimates
to directly elicited preferences in persons with persistent
asthma. 
METHODS: We used data from a one-year clinical trial
of adult asthmatics to derive preferences from the SF-36.
Preferences were estimated using ﬁve published algo-
rithms for converting SF-36 scores to non-choice based
preference estimates. Derived preferences were compared
to directly elicited visual analog scale (VAS) values.
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RESULTS: The average VAS value at baseline was 0.65
(SD = 0.19), 0.83 (SD = 0.14) at the end of the study 
and the average change score from baseline to end of
study for the VAS was 0.17 (SD = 0.20). The differences
between the VAS value and the derived preferences
ranged from -0.07 to 0.02 at baseline. Three of the ﬁve
95% conﬁdence intervals (CIs) for the difference between
derived preferences and VAS values at baseline included
zero. At the end of the study the mean of the VAS was
higher than the means for all of the derived preference
methods. The difference between the averages for the VAS
and the derived preferences ranged from 0.01 to 0.11 and
only one of the 95% CIs for the difference included zero.
The change scores for the VAS preferences were greater
than the derived preferences (Differences from 0.07 to
0.13). None of the 95% CIs for the difference in change
scores between VAS preferences and derived preferences
crosses zero.
CONCLUSIONS: The derivation methods produce valid
and responsive measures of patient preference. However,
the derived preference values differ from each other and
directly elicited preference values. Differences in the 
distributions of the directly elicited and derived prefer-
ences will affect inferences and can lead to differing 
conclusions in a cost-utility analysis.
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COST-EFFECTIVE TO THE GERMAN AND
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OBJECTIVE: To conduct a cost-effectiveness analysis,
from the perspectives of the German and French health-
care systems, of sequential IV/PO moxiﬂoxacin (MXF)
monotherapy versus standard comparators in hospital-
ized patients with community-acquired pneumonia (CAP)
requiring parenteral treatment. 
METHODS: Costs and consequences over 21 days 
were evaluated based on clinical cure rates 5–7 days 
post-treatment and resource use reported for the 
intention-to-treat population of the TARGET multina-
tional, prospective, randomized, open-label trial. This
trial compared sequential IV/PO MXF (400mg OD) to
IV/PO amoxicillin/clavulanate (AMC) (1.2g IV/625mg
PO TID) ± clarithromycin (CLA) (500mg BID) for 7–14
days in CAP patients. Since the treatment effect on
resource use (hospital length of stay [LOS]) was similar
across countries, resource data from all 10 countries were
pooled and valued using German and French unit prices
to estimate the CAP-related cost to the German Sickness
Funds and French public healthcare sector.
RESULTS: Compared to AMC ± CLA, treatment with
MXF resulted in 5.3% more patients having clinical cure
5–7 days post-therapy (95% CI -0.1%, 12.3%), a statis-
tically signiﬁcant faster response (return to apyrexia 1 day
sooner), and reduction in LOS by 0.81 days within 
the 21-day period. Treatment with MXF resulted in per
patient savings of €266 (Germany) and €381 (France)
compared to AMC ± CLA, primarily due to a shorter
LOS. Sensitivity analyses found these results to be robust
to several costing scenarios. Using bootstrap analysis of
the trial data, the probability of MXF being cost saving
in both countries was estimated to be 95% or greater,
while the probability of MXF being cost-effective was
commensurately higher for acceptability thresholds up to
€2,000 per additional patient cured. 
CONCLUSION: MXF shows clinical beneﬁts and is 
less costly versus AMC ± CLA in the treatment of CAP.
Treatment with MXF is likely to result in cost savings 
to the German and French public healthcare systems.
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OBJECTIVES: To evaluate the psychometric charac-
teristics of the Acute Bronchitis Symptom Severity 
(ABSS) Scale, a new 7-item bronchitis-speciﬁc instrument
designed to measure outcomes in chronic bronchitis (CB)
patients. 
METHODS: Data were obtained from the screening
phase of an international clinical trial comparing the
effectiveness of moxiﬂoxacin to a standard oral anti-
biotic treatment in treating an acute exacerbation of CB. 
Subjects had a primary diagnosis of CB (having presented
with ≥2 episodes of exacerbation in the preceding year,
FEV1 < 85% of predicted value, and history of smoking),
but were not currently experiencing an acute exacerba-
tion. Patients from 19 countries completed the ABSS 
(14 languages) for 8 consecutive evenings. Psychometric
characteristics evaluated were item performance, internal
consistency reliability (Cronbach’s alpha), day-to-day
reproducibility (intraclass correlation coefﬁcient (ICC)),
construct validity (based on correlation with the St.
George’s Respiratory Questionnaire (SGRQ)), and dis-
criminant validity (based on stratiﬁcation by pulmonary
function (FEV1 % predicted)).
RESULTS: 1935 patients were enrolled. Mean age was
63.4 years (± 9.7) and 68% were male. Mean CB dura-
tion was 11.7 (± 9.6) years, with a mean of 2.9 (± 1.3)
